Self-efficacy and motivation to quit during participation in a smoking cessation program
ABSTRACT The associations between failure to quit and posttreatment self-efficacy and motivation were examined among 600 African American smokers enrolled in a randomized trial testing the efficacy of bupropion for smoking cessation. Participants also received brief motivational counseling and were followed for 6 months. Baseline levels of self-efficacy and motivation for all participants were high (8.2 and 8.5 on a 10-point scale, respectively). Longitudinal analyses indicated that smokers who failed to quit were less likely than quitters to report high self-efficacy and motivation from posttreatment to follow-up. However, examination of mean self-efficacy and motivation scores at posttreatment and follow-up revealed that smokers continued to sustain high self-efficacy and motivation. Mean self-efficacy and motivation scores differed by less than 1 point from baseline levels, even though the majority of participants failed to quit smoking. Results suggest that unsuccessful participation in a smoking cessation program does not meaningfully reduce smokers' self-efficacy and motivation to quit.
- SourceAvailable from: Glenn E Good
[Show abstract] [Hide abstract]
- "Saliva samples from those who reported cessation at six months were assessed for cotinine (Benowitz, 2002; Jacob et al., 1981; Spierto et al., 1988). Other measures included single items to assess making a serious quit attempt for at least 24 hours (Ahluwalia et al., 2002; Centers for Disease Control and Prevention, 2007; Richter et al., 2001), motivation and confidence to quit (0–10 scale, 10=very motivated/ confident) (Boardman et al., 2005), number of five best friends who smoke (US Department of Commerce and Census Bureau, 2004), romantic partners' smoking status (created for this study), self-identification as a smoker (Waters et al., 2006), days consuming at least one drink of alcohol (Centers for Disease Control and Prevention, 1997), servings of fruits and vegetables eaten per day (Resnicow et al., 2003), and dependence using the 10-item Hooked on Nicotine Checklist (Wellman et al., 2004; Wellman et al., 2005). "
ABSTRACT: To examine the efficacy of four individually-delivered Motivational Interviewing counseling sessions for smoking cessation versus a matched intensity comparison condition. From 2006-2009, students attending college in the Midwest smoking at least 1 of 30 days were recruited regardless of their interest in quitting. 30 fraternities and sororities were randomized, resulting in 452 participants. No significant differences were found for 30-day cessation between treatment and comparison at end of treatment (31.4% vs 28%, OR=1.20, 95% CI 0.72,1.99) or at follow-up (20.4% vs 24.6%, OR=0.78, 95% CI 0.50,1.22). Predictors of cessation at follow-up, regardless of condition, included more sessions attended (OR 1.2, 95% CI 1.1,1.8) and more cigarettes smoked in 30 days at baseline (OR 4.7, 95% CI 2.5,8.9). The odds of making at least one quit attempt were significantly greater for those in the smoking group at end of treatment (OR 1.75, 95% CI 1.11,2.74) and follow-up (OR 1.66, 95% CI 1.11,2.47). Modeling showed reduction in days smoked for both groups. At end of treatment, more frequent smokers in the treatment condition had greater reductions in days smoked. Motivational Interviewing for smoking cessation is effective for increasing cessation attempts and reducing days smoked in the short run.Preventive Medicine 11/2010; 51(5):387-93. DOI:10.1016/j.ypmed.2010.08.018 · 2.93 Impact Factor
[Show abstract] [Hide abstract]
- "Sixty percent of patients who attempt to stop smoking have had previous attempts to quit (Wilkes et al 2005). They often require repeated help from health professionals to eventually overcome their addiction (Errard-Lalande 2005) but the motivation that brings smokers back to try again will often lead to eventual success (Boardman et al 2005). The effi cacy of bupropion appears not to diminish with repeated exposure (Rauhut et al 2005). "
ABSTRACT: Cigarette smoking remains the largest preventable cause of premature death in developed countries. Until recently nicotine replacement therapy (NRT) has been the only recognised form of treatment for smoking cessation. Bupropion, the first non-nicotine based drug for smoking cessation was licensed in the United States of America (US) in 1997 and in the United Kingdom (UK) in 2000 for smoking cessation in people aged 18 years and over. Bupropion exerts its effect primarily through the inhibition of dopamine reuptake into neuronal synaptic vesicles. It is also a weak noradrenalin reuptake inhibitor and has no effect on the serotonin system. Bupropion has proven efficacy for smoking cessation in a number of clinical trials, helping approximately one in five smokers to stop smoking. Up to a half of patients taking bupropion experience side effects, mainly insomnia and a dry mouth, which are closely linked to the nicotine withdrawal syndrome. Bupropion is rarely associated with seizures however care must be taken when co-prescribing with drugs that can lower seizure threshold. Also, bupropion is a potent enzyme inhibitor and can raise plasma levels of some drugs including antidepressants, antiarrhythmics and antipsychotics. Bupropion has been shown to be a safe and cost effective smoking cessation agent. Despite this, NRT remains the dominant pharmacotherapy to aid smoking cessation.International Journal of COPD 02/2008; 3(1):45-53. · 2.73 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: To determine home smoking restrictions (HSR) predictors among African American light smokers (smoke <or= 10 cigarettes per day). Data were obtained from a clinical trial testing the efficacy of nicotine gum and counseling among 755 African American light smokers. Forty percent reported adopting HSR at week 26. Implementing HSR increased with higher baseline confidence to quit (P <0.0001) and female gender (P = 0.019) and decreased with older age (P = 0.016) and reduced confidence to quit between baseline and week 26 (P <0.0001). Confidence to quit, gender, and age are important factors to incorporate into interventions enhancing the adoption of HSR.American journal of health behavior 01/2010; 34(1):110-8. DOI:10.5993/AJHB.34.1.13 · 1.31 Impact Factor